-Bloomberg
SVB Leerink Maintains Underperform on AbbVie, Lowers Price Target to $135
SVB Leerink analyst David Risinger maintains AbbVie (NYSE:ABBV) with a Underperform and lowers the price target from $140 to $135.
Related Posts
‘France Eyeing Antitrust Action Against Apple’ – Axios
https://www.axios.com/2023/04/11/apple-france-antitrust-action-advertising-tracking
The French Competition Authority is likely to move forward soon with an antitrust investigation into Apple over complaints tied to 2021 changes to its app tracking policies, sources told Axios.
Societe Generale Maintains Buy on Alphabet, Lowers Price Target to $132
Societe Generale analyst Christophe Cherblanc maintains Alphabet (NASDAQ:GOOG) with a Buy and lowers the price target from $147 to $132.
Belong Acquisition Corp. Announces Redemption Amount Of Its Public Shares; Approximately $10.23/ Share
Belong Acquisition Corp. (NASDAQ:BLNG) (the "Company"), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that the per-share redemption price for the